Categories: News

EDAP TMS SA to Announce First Quarter 2022 Financial Results on May 17, 2022

Company to host conference call and webcast on, Wednesday, May 18that 8:30 am EDT

LYON, France, May 10, 2022 – EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31st, 2022 after the markets close on Tuesday, May 17th, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Wednesday, May 18th, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Wednesday, May 18th@ 8:30am Eastern Time
Domestic:        877-451-6152
International:   201-389-0879
Passcode:        13728747
Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1541898&tp_key=e83b07e195

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit focalone.com, http://www.edap-tms.com, and us.hifu-prostate.com.

Company contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
212-915-2568
jfraunces@lifesciadvisors.com

 

Staff

Recent Posts

Functional Brands Inc. to Participate at the Sidoti Year End Virtual Investor Conference

Lake Oswego, Oregon--(Newsfile Corp. - December 8, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a…

9 minutes ago

Cheelcare Has a Record Month of Sales and Celebrates Milestone of 2,000 Companions Sold

Markham, Ontario--(Newsfile Corp. - December 8, 2025) - Cheelcare (TSXV: CHER), a Canadian innovator in…

1 hour ago

SJTU International Gen Z Students Explore Shanghai’s Innovation Ecosystem

SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- Shanghai Jiao Tong University's Antai Global Summer Program (AGSP)…

2 hours ago

Evotec Closes Sale of Just – Evotec Biologics’ Toulouse Site to Sandoz

All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing…

5 hours ago

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health…

8 hours ago

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment…

8 hours ago